Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve
- 222 Downloads
This retrospective study was carried out to evaluate whether increasing the starting dose of FSH stimulation above the standard dose of 150 IU/day in patients with low predicted ovarian reserve can improve IVF outcomes.
A total of 122 women aged less than 36 years in their first cycle of IVF were identified as having likely low ovarian reserve based on a serum AMH measurement below 14 pmol/l. Thirty five women were administered the standard dose of 150 IU/day FSH, while the remaining 87 received a higher starting dose (200–300 IU/day FSH). There were no significant differences in age, BMI, antral follicle count, serum AMH, FSH or aetiology of infertility between the two dose groups.
No significant improvement in oocyte and embryo yield or pregnancy rates was observed following an upward adjustment of FSH starting dose. While increasing the dose of FSH above 150 IU/day did not produce any adverse events such as OHSS, it did consume an extra 1,100 IU of FSH per IVF cycle.
The upward FSH dose adjustment in anticipation of low ovarian reserve can not be advocated as it is both expensive and of no proven clinical value.
KeywordsAnti-Müllerian hormone Predicted poor ovarian reserve controlled ovarian hyper-stimulation FSH dose adjustment IVF
Dharmawijaya Lekamge was supported by an International Post-Graduate Research Scholarship (IPRS) and Adelaide University Scholarship. We wish to thank staff at Repromed for friendly assistance.
- 3.Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard’ dose of 150 IU/day in ‘standard’ patients undergoing IVF/ICSI treatment. Hum Reprod. 2003;18:2275–82. doi: 10.1093/humrep/deg472.PubMedCrossRefGoogle Scholar
- 5.Popovic-Todorovic B, Loft A, Lindhard A, Bangsboll S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003;18:781–7. doi: 10.1093/humrep/deg181.PubMedCrossRefGoogle Scholar
- 11.Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77:468–71. doi: 10.1016/S0015-0282(01)03201-0.PubMedCrossRefGoogle Scholar
- 12.Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–9. doi: 10.1016/j.fertnstert.2004.03.061.PubMedCrossRefGoogle Scholar
- 14.Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod. 2005;20:3178–83. doi: 10.1093/humrep/dei203.PubMedCrossRefGoogle Scholar
- 16.Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin—releasing hormone agonist—gonadotropin treatment. Hum Reprod. 2005;20:915–22. doi: 10.1093/humrep/deh718.PubMedCrossRefGoogle Scholar
- 21.Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril. 2007;87:223–6. doi: 10.1016/j.fertnstert.2006.06.019.PubMedCrossRefGoogle Scholar
- 23.Harrison RF, Jacob S, Spillane H, Mallon E, Hennelly B. A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertil Steril. 2001;75:23–31. doi: 10.1016/S0015-0282(00)01643-5.PubMedCrossRefGoogle Scholar
- 24.Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod. 1999;14:622–7. doi: 10.1093/humrep/14.3.622.PubMedCrossRefGoogle Scholar
- 25.Hoomans EH, Mulder BB. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. J Assist Reprod Genet. 2002;19:470–6. doi: 10.1023/A:1020358419073.PubMedCrossRefGoogle Scholar
- 26.Yong PY, Brett S, Baird DT, Thong KJ. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril. 2003;79:308–15. doi: 10.1016/S0015-0282(02)04583-1.PubMedCrossRefGoogle Scholar
- 28.Popovic-Todorovic B, Loft A, Ziebe S, Andersen AN. Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in “standard” patients treated with 150 IU/day during the first cycle. Acta Obstet Gynecol Scand. 2004;83:842–9. doi: 10.1111/j.0001-6349.2004.00573.x.PubMedCrossRefGoogle Scholar
- 32.Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod. 2005;20:923–7. doi: 10.1093/humrep/deh688.PubMedCrossRefGoogle Scholar
- 34.Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod. 2005;20:611–5. doi: 10.1093/humrep/deh663.PubMedCrossRefGoogle Scholar